Advanced searches left 3/3

Everolimus - Crossref

Summarized by Plex Scholar
Last Updated: 07 September 2022

* If you want to update the article please login/register

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

Background: There is unmet medical need for patients with human epidermal growth factor 2-positive central nervous system metastases, which is an improving outcome. Patients with trastuzumab-pretreated, HER2+ breast cancer brain metastasis without prior therapy with a mammalian target of rapamycin inhibitor were eligible. In 21-d cycles, patients were given lapatib and everolimus every day and capecitabine twice a day. Results: A total of 19 participants were registered and treated with the study drug u2a7e1 ton. The median age of breast cancer treatment was 58. 5 years, while the average number of drugs for metastatic breast cancer was 2. 5. A total of 63% had undergone CNS radiation or surgical resection, as well as CNS radiation. Due to increased tolerability, Phase II proceeded with capecitabine at 750 mg/m 2 during Phase II. Of 11 people evaluated for 12-week CNS ORR, 3 had partial response, and 7 had stable disease. 28 percent was the highest CNS ORR in eligible participants.

Source link: https://doi.org/10.1177/1758835918807339


The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance

Pancreatic neuroendocrine tumors are often inoperable at diagnosis, and pancreatic neuroendocrine tumors are often inoperable at diagnosis. BON1 and BON1 RR1 and BON1 RR2 all showed resilient resistance after 24 weeks of continuous exposure to 10 nM everolimus, BON1 RR1 and BON1 RR2 showed excellent resistance with cellular survival rates of 96. 7 percent and 92. 3 percent, respectively. The control cell line demonstrated sensitivity to ten nM everolimus, with cell survival falling to 54. 7 percent from 54. 7 percent. Following a drug holiday of 13 weeks, both resistant cell lines did not recover sensitivity over time and demonstrated persistent resistance after long-term resistance. The causes of resistance in our cell line model included morphological adjustments, G1 cell cycle arrest, reduced CDK1 expression, and reduced autophagy. Everolimus with the PI3K/u03b1 inhibitor BYL719 re-established sensitivity through GSK3 inhibition and autophagy restoration. We propose that GSK3 over-activation, as well as decreased baseline IRS-1 protein levels and decreased autophagy, may be a key characteristic of everolimus resistance and, hence, a potential therapeutic goal.

Source link: https://doi.org/10.1530/erc-18-0159


Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1 -Mutant Diffuse Intrinsic Pontine Glioma

Abstract In a quarter of children with diffuse intrinsic pontine glioma, a quarter of whom have diffuse intrinsic pontine glioma, there are no ACVR1 inhibitors approved for the condition. Everolimus inhibited ABCG2 and ABCB1 transporters and was synergistic in DIPG cells when mixed with vandetanib in vitro, in comparison to mTOR. Four patients with ACVR1-mutant DIPG were treated with vandetanib plus an mTOR inhibitor, raising the dosing and toxic profile of this combination for future clinical trials. In ACVR1, twenty-five percent of patients with incurable brainstem tumor DIPG had somatic mutations, but there are no approved drugs targeting the receptor. We discover and analyze the novel combination of vandetanib and everolimus in these children using both experimental and clinical studies using artificial intelligence.

Source link: https://doi.org/10.1158/2159-8290.cd-20-1201


Everolimus loaded NPs with FOL targeting: preparation, characterization and study of its cytotoxicity action on MCF-7 breast cancer cell lines

The mortality risks of breast cancer are largely due to a lack of appropriate facilities for diagnosis and detection, as well as high cost effective of the therapy. A corresponding line in BC therapy may be provided to Everolimus loaded PLGA-TPGS NPs targeting folate and investigating their toxicity effect on human MCF-7 BC cell lines. Formulation B of EV loaded NPs was found to be the lowest PS 100-u00b112. 7 nm, PDI 0. 152, and have ZP, -23. 2. 5. EV formulated in NPs had better results against the MCF-7 BC cell line than EV free and EV loaded NPs formulation B, which had even better therapeutic effect than A, C, and D formulations. When treated the MCF-7 BC cells with EV loaded NPs formulation B, HIF-1A mRNA gene expression was reduced in compared to expression in untreated cells.

Source link: https://doi.org/10.35516/jjps.v15i1.286


Five-year overall survival of metastatic renal cell carcinoma patients treated with everolimus after progression on bevacizumab: a prospective multicenter study CRAD001LRU02T

The median overall survival was 17. 4 months in a CRAD001LRU02T research of everolimus for metastatic renal cell carcinoma patients previously treated with bevacizumab u00b1 interferon. In a multicenter study, survival data was obtained from 37 patients with bevacizumab-refractory renal cell carcinoma (everolimus) in a complete prospective multicenter study. Patients were mainly male, with 89 percent having ECOG performance status of 0/1, 51% in combination with interferon, and 38/62% had MSKCC favorable/intermediate risk disease. The median duration of a second line of everolimus was 315 days. In 5 patients, confirmed objective tumor responses were present. One patient ended Everolimus therapy on their own initiative after a return to systemic lupus erythematosus, and one patient sustained 14 days of hospitalization due to grade 3 hyperglycemia. Everolimus had an estimated 5-year survival rate of 16. 2 percent for bevacizumab-resistant metastatic renal cell carcinoma.

Source link: https://doi.org/10.17650/1726-9776-2017-13-4-40-44


A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients

Purpose The aim of the stent's second-generation drug-eluting stent's restosis risk factors, as well as other relevant research. Thus, the study investigated the occurrence and predictors of coronary heart disease in patients with percutaneous coronary disease treated with EES. Including CHD patients with EES who had undergone PCI with EES was remarkably high. Results Within one year of surgery, 20 patients developed in-stent restenosis, while 215 patients did not experience in-stent restenosis, resulting in a 1-year in-stent restenosis rate of 8. 5%. Based on these independent predictive factors, the In-stent restenosis risk prediction tool, Then, the in-stent restenosis risk prediction tool, was established, which showed an excellent success in predicting in-stent restenosis risk by receiver operating characteristic analysis. In-stent restenosis risk prediction models based on diabetes mellitus, hypercholesteemia, SUA, HsCRP, and patients with two target lesions can help identify in-stent restenosis risk in patients with CHD who underwent post-PCI with EES.

Source link: https://doi.org/10.3389/fcvm.2022.857922


A comparative study of combination treatments in metastatic 4t1 cells: everolimus and 5- fluorouracil versus lithium chloride and 5-fluorouracil

Background : Combination therapy has been one of the most innovative and effective treatment options for malignancy treatment, because it can specifically influence multiple signaling pathways involved in cancer growth and progression. In 4T1 metastatic breast cancer cells, the effects of 5-fluorouracil in combination with everolimus or lithium chloride were evaluated in comparison to both control and each other in the present study. Conclusion : The findings revealed that 5FU-LiCl increased cell cytotoxicity and apoptosis significantly more than EVE-5FU, but that their use in pre-clinical models has sparked controversy.

Source link: https://doi.org/10.3897/pharmacia.69.e85358


Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

The preclinical synergistic anticancer drug everolimus, as well as oral glutaminase inhibitor telaglenastat, revealed preclinical synergistic anticancer activity, leading to improved safety and efficacy data in a phase I study of 2L+ renal cell carcinomas. In patients with advanced/metastatic RCC in the 3L+ group, this research compared telaglenastat plus everolimus to placebo plus everolimus. PFS was 3. 8 months for TelaE relative to 1. 9 months for PboE [HR, 0. 64; 95% confidence interval, 0. 079], one-sided P = 0. 079] at median follow-up of 7. 5 months. SD was found in Eleven patients on PboE. Results: TelaE was well tolerated and improved PFS in patients with mRCC who were previously treated with TKIs and checkpoint inhibitors.

Source link: https://doi.org/10.1158/1078-0432.ccr-22-0061

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions